Mark A. Feitelson
Affiliations: | Biology | Temple University, Philadelphia, PA, United States |
Area:
Virology Biology, Biochemistry, Cell BiologyWebsite:
https://biography.omicsonline.org/united-states-of-america/temple-university/mark-a-feitelson-10540Google:
"Mark Allen Feitelson" OR "Mark A Feitelson"Bio:
https://www.researchgate.net/profile/Mark-Feitelson
https://books.google.com/books?id=8ScoAQAAIAAJ
Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Felix O. Wettstein | grad student | 1979 | UCLA School of Medicine (Microtree) | |
| (Tryptic peptide mapping of the structural proteins in the Shope papilloma virus : characterization of proteins from sodium duodecyl sulfate-polyacrylamide gels using the Bolton-Hunter reagent) | ||||
Children
Sign in to add trainee| Ke Yuan | grad student | 2011 | Temple University |
| Tiffany I. Friedman | grad student | 2012 | Temple University |
| Vaishnavi Sambandam | grad student | 2014 | Temple University |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Zhang N, Wang F, Yang X, et al. (2024) TMEM43 promotes the development of hepatocellular carcinoma by activating VDAC1 through USP7 deubiquitination. Translational Gastroenterology and Hepatology. 9: 9 |
| Feitelson MA, Arzumanyan A, Spector I, et al. (2022) Hepatitis B x (HBx) as a Component of a Functional Cure for Chronic Hepatitis B. Biomedicines. 10 |
| Medhat A, Arzumanyan A, Feitelson MA. (2021) Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma. Oncotarget. 12: 2421-2433 |
| McBrearty N, Arzumanyan A, Bichenkov E, et al. (2021) Short chain fatty acids delay the development of hepatocellular carcinoma in HBx transgenic mice. Neoplasia (New York, N.Y.). 23: 529-538 |
| Hurwitz SJ, McBrearty N, Arzumanyan A, et al. (2021) Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator. Viruses. 13 |
| Feitelson MA, Arzumanyan A, Kulathinal RJ, et al. (2015) Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Seminars in Cancer Biology |
| Feitelson MA, Bonamassa B, Arzumanyan A. (2014) The roles of hepatitis B virus-encoded X protein in virus replication and the pathogenesis of chronic liver disease. Expert Opinion On Therapeutic Targets. 18: 293-306 |
| Wu G, Liu B, Zhang Y, et al. (2013) Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrobial Agents and Chemotherapy. 57: 5344-54 |
| Song K, Han C, Zhang J, et al. (2013) Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells. Hepatology (Baltimore, Md.). 58: 1681-92 |
| Arzumanyan A, Reis HM, Feitelson MA. (2013) Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nature Reviews. Cancer. 13: 123-35 |